Skip to main content
logo
Pelthos Therapeutics Inc. (PTHS)
NYSEAMERICAN: PTHS · Real-Time Price · USD
22.90
+0.16 (0.70%)
At close: Apr 8, 2026, 4:00 PM EDT
22.90
0.00 (0.00%)
After-hours: Apr 8, 2026, 6:30 PM EDT

Pelthos Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
16.8----
Cost of Revenue
5.221.18-0.390.21
Gross Profit
11.58-1.18--0.39-0.21
Selling, General & Admin
41.436.394.281.930.63
Research & Development
--2.58--
Amortization of Goodwill & Intangibles
1.56----
Operating Expenses
42.996.396.861.930.63
Operating Income
-31.41-7.57-6.86-2.32-0.84
Interest Expense
-3.01-0.79-0.52-0.14-0
Interest & Investment Income
0.010.4---
Other Non Operating Income (Expenses)
-14.98----
EBT Excluding Unusual Items
-49.4-7.96-7.38-2.46-0.84
Merger & Restructuring Charges
-1.02----
Asset Writedown
-0.29----
Other Unusual Items
----0.24
Pretax Income
-50.71-7.96-7.38-2.46-0.6
Income Tax Expense
-7.39----
Net Income
-43.32-7.96-7.38-2.46-0.6
Net Income to Common
-43.32-7.96-7.38-2.46-0.6
Shares Outstanding (Basic)
2100-
Shares Outstanding (Diluted)
2100-
Shares Change (YoY)
237.34%336.69%193.25%--
EPS (Basic)
-23.04-14.27-57.82-56.48-
EPS (Diluted)
-23.04-14.27-57.82-56.48-
Free Cash Flow
-22.69-5.79-0.98-1.57-1.59
Free Cash Flow Per Share
-12.06-10.39-7.68-36.00-
Gross Margin
68.94%----
Operating Margin
-187.01%----
Profit Margin
-257.93%----
Free Cash Flow Margin
-135.09%----
EBITDA
-29.12---1.63-
EBITDA Margin
-173.40%----
D&A For EBITDA
2.29--0.69-
EBIT
-31.41-7.57-6.86-2.32-0.84
EBIT Margin
-187.01%----
Revenue as Reported
16.8----
Updated Mar 19, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q